Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations
"I am thrilled to join Atossa at such a pivotal time in the company's history," said Mr. Parks. "Atossa's commitment to advancing innovative therapies in oncology, particularly in breast cancer, aligns perfectly with my passion for communicating impactful stories to the healthcare, investor, and patient communities. I look forward to joining this dedicated team on this journey and continue building value and awareness among Atossa's multiple stakeholders."SEATTLE, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) today announced the appointment of Michael Parks as Vice President of Investor and Public Relations. Mr. Parks brings nearly 30 years of investor relations and corporate communications experience working globally within the biopharmaceutical and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
2024年8月20日，西雅圖（GLOBE NEWSWIRE）- Atossa Therapeutics, Inc. （納斯達克：ATOS）今天宣佈任命邁克爾·帕克斯爲投資者和公共關係副總裁。帕克斯先生在生物製藥和醫療保健行業全球範圍內擁有近30年的投資者關係和企業傳播經驗。他將負責公司、高管和數字通信、投資者關係、思想領袖和品牌等事務。Atossa是一家臨床階段的生物製藥公司，在癌症領域開發創新藥物，重點研究乳腺癌等領域的重大未滿足醫療需求。
"We are excited to welcome Michael to Atossa. Michael is a highly seasoned corporate communications professional with experience across healthcare companies of all sizes and stages of development," said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. "His extensive experience and multidisciplined approach to communications will serve Atossa well in advancing the story of the immense potential of the (Z)-endoxifen platform for patients and translating this opportunity into value for investors and other stakeholders."
"我們很高興歡迎邁克爾加入Atossa。邁克爾是一位經驗豐富的企業傳播專業人士，在醫療保健公司的各種規模和發展階段工作過，"說Steven Quay博士，Atossa總裁兼首席執行官。 "他豐富的經驗和多學科的溝通方法將有助於Atossa推動(Z)-endoxifen平台的潛力，並將這一機會轉化爲投資者和其他利益相關者的價值。"
Prior to joining Atossa, Mr. Parks was Vice President of Investor Relations at both PAVmed, a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors; and its publicly traded subsidiary, Lucid Diagnostics, a commercial-stage, cancer prevention medical diagnostics company. Previously, Mr. Parks led corporate communications and public affairs efforts at Liquidia Corporation after serving more than a decade as the Founder and President of Pitch360, a consulting firm which provided a full spectrum of investor relations, corporate communications and public affairs services to private and small-cap biopharmaceutical companies. Earlier in his career he served as the Vice President of Corporate Communications at Centocor, a Johnson & Johnson Company, and held roles of increasing responsibility at Pfizer, Pharmacia, and Searle Pharmaceuticals.
在加入Atossa之前，帕克斯先生曾在PAVmed，在器械，診斷和數字健康領域經營多元化商業化階段的醫療技術公司，以及其公開交易的子公司Lucid Diagnostics擔任投資者關係副總裁，並領導過Liquidia Corporation的企業傳播和公共事務工作，在私人和小型生物製藥公司中提供了全方位的投資者關係、企業傳播和公共事務服務的諮詢公司Pitch360的創始人和總裁超過十年的經營管理。在職業生涯早期，他曾擔任輝瑞、法瑪西亞和西爾製藥等公司的企業傳播副總裁，並在約翰遜·約翰遜的Centocor公司擔任企業傳播副總裁，並擔任越來越重要的職務。
"I am thrilled to join Atossa at such a pivotal time in the company's history," said Mr. Parks. "Atossa's commitment to advancing innovative therapies in oncology, particularly in breast cancer, aligns perfectly with my passion for communicating impactful stories to the healthcare, investor, and patient communities. I look forward to joining this dedicated team on this journey and continue building value and awareness among Atossa's multiple stakeholders."
"我很高興在這個公司的歷史轉折點加入Atossa，"帕克斯先生說。 "Atossa致力於推動癌症領域創新療法，特別是乳腺癌，與我向醫療保健、投資者和患者社區傳達有影響力的故事的熱情完美契合。我期待着加入這個專注的團隊，繼續在Atossa的多個利益相關者中創造價值和意識。"
About Atossa Therapeutics
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. For more information, please visit .
關於Atossa Therapeutics
Atossa Therapeutics，Inc.是一家臨床階段的生物製藥公司，致力於在癌症領域開發具有重大未滿足醫療需求的創新藥物，目前的重點是乳腺癌和因癌症治療而引起肺損傷。有關更多信息，請訪問 .
Contact:
聯繫方式：
Michael Parks
VP, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
邁克爾·帕克斯
投資者和公共關係副總裁
484-356-7105
michael.parks@atossainc.com
譯文內容由第三人軟體翻譯。
